The federal research and development (R&D) tax credit requires careful separation of research eligibility, expense substantiation, contract funding, and the applicable tax-year rules. Internal Revenue Code Section 41 governs the credit. Sections 174 and 174A govern the treatment of research or experimental expenditures, with important changes enacted in 2025.

This study examines the Sutherland decisions cited in discussions of R&D compliance and explains their actual scope. Those decisions do not establish new Section 41 experimentation, funding, or consistency rules. The practical implications for engineering firms, manufacturers, and software developers instead come from the research-credit statute, regulations, and cases that actually address those provisions.

The Sutherland Jurisprudential Landscape: A Procedural and Substantive Intersection

In Sutherland v. Commissioner, 155 T.C. 95 (2020), also designated 155 T.C. No. 6, the Tax Court addressed the effective date of Section 6015(e)(7), an innocent-spouse review provision. It held that the provision applies to petitions filed on or after July 1, 2019. Because the petition in that case preceded the effective date, the provision did not limit the evidence the taxpayer could introduce.

For cases to which Section 6015(e)(7) applies, review is de novo and rests on the administrative record plus newly discovered or previously unavailable evidence. This provision does not establish an administrative-record-only rule for ordinary Section 41 disputes. Sutherland therefore does not make an R&D examination the taxpayer’s final opportunity to present technical evidence.

The substantive innocent-spouse decision involving Donna Sutherland and her husband Scott’s draft-beer-system business was Sutherland v. Commissioner, T.C. Memo. 2021-110. The source’s attribution of those facts to T.C. Memo. 2023-150 was incorrect. The court denied equitable relief under Section 6015(f); it did not decide whether the installation business performed qualified research or establish research-credit penalty standards.

Sutherland Lumber-Southwest, Inc. v. Commissioner, 114 T.C. 197 (2000), concerned employer deductions for employees’ nonbusiness use of company aircraft under the then-applicable Section 274 rules. Its cost-versus-fringe-benefit analysis does not establish a right to deduct all research costs or determine substantial rights in research results.

Comparative Procedural Impact of Sutherland Rulings on R&D Strategy

Technical Uncertainty and the Professional Services Hurdle

Professional engineering and architectural work must satisfy the same statutory eligibility requirements as other research. Complexity, customization, professional qualifications, and an innovative end product do not establish eligibility by themselves.

The engineering decision discussed in the source is Phoenix Design Group, Inc. v. Commissioner, rather than Sutherland. The court found that the taxpayer had not established qualified research. Smith v. Commissioner concerned a separate architectural firm’s funded-research dispute. Treating these as one line of Sutherland holdings obscures both the facts and the procedural outcomes.

The uncertainty inquiry considers whether the information available to the taxpayer establishes capability, method, or appropriate design. Uncertainty about appropriate design can qualify; it is not limited to capability or methodology. Unsettled appearance preferences or customer specifications alone do not establish qualifying technological uncertainty.

The Process of Experimentation and the Evaluation of Alternatives

Treasury Regulation Section 1.41-4 requires a process that evaluates alternatives to resolve qualifying uncertainty. Modeling, simulation, or systematic trial and error may satisfy that requirement. The regulation does not prescribe a single laboratory procedure or require an advance beyond knowledge common to the taxpayer’s field.

Iterative engineering is not categorically excluded. The relevant question is whether the activities actually evaluate alternatives to resolve uncertainty, rather than merely implement a known solution. Records should identify the unresolved issue, the alternatives considered, and how the results informed the design.

The substantially-all threshold is 80% of the relevant research activities, measured on a cost or other consistently applied reasonable basis. It applies separately to the business component under review. Where appropriate, the shrinking-back rule allows analysis of a smaller component. Routine quality-control testing and research after commercial production are subject to separate exclusions; installation timing alone is not a complete legal test.

The Four-Part Test of IRC Section 41(d)

The Funded Research Exclusion and the Contract Analysis

Section 41(d)(4)(H) and Treasury Regulation Section 1.41-4A(d) exclude research to the extent it is funded by another person. For the research performer, the analysis considers entitlement to payment and retained substantial rights. A performer retaining no substantial rights is treated as fully funded. When substantial rights are retained, payments may offset otherwise eligible costs, subject to the allocation rules. Amounts contingent on successful research results are not treated as funding.

All relevant agreements must be considered. A fixed-price label, professional-standard clause, or general commercial exposure cannot decide the issue by itself. The research performer’s analysis also differs from that of a customer claiming contract research expenses; the parties should not interchange their respective payment-risk tests.

The Role of Local Law and Milestone Payments

In the 2024 Smith decision discussed in the source, the Tax Court denied the Commissioner’s summary-judgment motion. Contract milestones and rights provisions required further consideration. That procedural result did not establish that all of the claimed research expenses qualified.

In System Technologies, Inc. v. Commissioner, the court considered Indiana law and whether a customer could recover progress payments if the promised product was not delivered. The funding analysis addressed the interaction between the contracts, warranty provisions, and remedies for total breach. It did not establish a universal rule that a warranty or progress-payment arrangement makes research unfunded.

• Contractual silence: Review applicable law and the entire agreement before concluding that the performer retains rights.
• Shared rights: Substantial rights need not be exclusive, but incidental experience gained from doing the work is insufficient.
• Warranty provisions: Determine whether the actual remedies make payment contingent on research success.

The Consistency Rule and Historical Baselines

Section 41(c)(6) requires consistent treatment of qualified research expenses in the credit year and the relevant historical calculation. This requirement comes from the research-credit provisions, not Sutherland. Audio Technica U.S., Inc. v. United States addresses research-credit computation and litigation issues, but it does not turn unrelated innocent-spouse decisions into credit authorities.

A closed assessment period does not eliminate the need to establish historical amounts used to calculate an open year’s credit. If a newly claimed expense category also existed in relevant historical years, the taxpayer must address the corresponding historical treatment rather than selectively understating the baseline.

The regular credit generally uses a fixed-base percentage and preceding four-year average gross receipts, subject to statutory limitations and startup rules. The 1984–1988 period applies to the fixed-base calculation for certain established businesses, not every claimant. The alternative simplified credit generally compares current expenses with 50% of the preceding three-year average, with a separate rule where a prior year has no qualified research expenses. A credit does not invariably require spending to exceed the immediately preceding year’s amount.

Coordination with Other Credits: The United Therapeutics Decision

United Therapeutics Corporation v. Commissioner, 160 T.C. 253 (2023), affirmed by the Fourth Circuit on June 24, 2024, addressed coordination between the research credit and the Section 45C orphan drug credit. Expenses used for the orphan drug credit cannot also generate the research credit for that year. Overlapping expenses that otherwise meet the research-expense definition must nevertheless enter the relevant historical research-expense measure for subsequent years.

The decision prevents selective omission of overlapping costs from that historical measure. Companies claiming both incentives should maintain a reconciliation showing the expense classification and treatment in each affected year.

Summary of the Consistency Rule Mechanics

Documentation Standards and Research-Credit Refund Claims

The IRS’s 2021 guidance initially identified five items for research-credit refund claims. For claims postmarked on or after June 18, 2024, the IRS waived the initial submission of individual researchers’ names and the information each individual sought to discover. The remaining items are identification of all relevant business components, research activities for each component, and total qualified wage, supply, and contract research expenses.

These are claim-validity requirements, not substitutes for proving eligibility during an examination. The IRS may request further evidence. Its January 2026 procedural update extends the transition period for perfecting covered deficient claims through January 10, 2027.

The Transition to the New Form 6765

Under the December 2025 instructions, Section G is optional for tax years beginning before 2026 and required for years beginning after 2025, subject to exceptions. Those exceptions include certain qualified small businesses making the payroll-tax election and original-return filers meeting both the $1.5 million controlled-group qualified-expense threshold and the $50 million prior-three-year average-gross-receipts threshold.

When Section G is required, detailed entries generally cover business components accounting for at least 80% of qualified research expenses, limited to 50 components, with remaining components aggregated. The instructions contain additional group and special rules. These form requirements must be distinguished from refund-claim submission requirements.

Betz v. Commissioner, T.C. Memo. 2023-84, illustrates the risks of inadequate substantiation and an unsuccessful professional-reliance defense to accuracy-related penalties. A consultant’s involvement does not automatically establish reasonable cause. The taxpayer must substantiate the claimed activities and costs and the basis for any reliance defense.

Best Practices for Modern Substantiation

• Time allocation: Maintain reliable project and activity records supporting wage allocations. Contemporaneous time tracking is useful, but no universal rule makes one specific timesheet system mandatory.
• Technical design records: Preserve alternatives, calculations, models, test results, design revisions, and explanations of unresolved technical questions.
• Expense linkage: Reconcile technical activities to payroll, supplies, and eligible contract research costs.
• Supervision: Apply the regulatory distinction between direct supervision and higher-level management. A senior title does not itself qualify or disqualify wages; actual services control.

Section 174 Amortization and the Restoration of Domestic Expensing

For tax years beginning in 2022–2024, the Tax Cuts and Jobs Act generally required capitalization of specified research expenditures and amortization over five years for domestic research or fifteen years for foreign research, beginning at the midpoint of the tax year.

Public Law 119-21, enacted July 4, 2025, added Section 174A. Domestic research or experimental expenditures are generally deductible for tax years beginning after December 31, 2024, subject to applicable rules. Taxpayers may elect capitalization and amortization over at least 60 months. Foreign research remains subject to fifteen-year amortization under Section 174.

Transition provisions permit accelerated recovery of remaining domestic balances from 2022–2024 over one or two years and provided a time-limited retroactive election for eligible small businesses. Eligibility, deadlines, and procedures must be checked under the statute and Revenue Procedure 2025-28. These are enacted provisions, rather than pending legislative proposals.

For years beginning after 2024, Section 280C(c) generally reduces the domestic research expenditures otherwise deducted or capitalized by the research credit, unless the taxpayer elects a reduced credit. The reduced-credit computation uses the maximum corporate tax rate. The source’s assertion of an automatic 21% permanent benefit for 2022–2024 is too broad; those years require analysis under their applicable provisions and elections.

The Reasonableness of Research Expenditures

The historical Section 174(e) and Treasury Regulation Section 1.174-2(a)(9) addressed reasonable expenditure amounts. The statutory framework has since changed, including the creation of Section 174A, so the applicable year matters. No Sutherland decision supplies a blanket exemption from scrutiny of research payments. Taxpayers should document the nature, amount, recipient, and business purpose of their expenses and evaluate any applicable allocation or related-party rules.

Impact of Legislative Changes on R&D Financials